When to Use Intravenous Iron for Iron Deficiency Anemia
Intravenous iron should be used as first-line therapy when patients have intolerance to oral iron, fail to respond to oral iron supplementation, have hemoglobin below 10 g/dL, have active inflammatory conditions, or have malabsorption disorders. 1, 2, 3
Primary Indications for IV Iron
Oral Iron Failure or Intolerance
Patients who do not tolerate oral iron due to gastrointestinal side effects (nausea, constipation, dyspepsia) should receive IV iron. 4, 1, 3 These adverse effects occur frequently and lead to poor compliance with oral supplementation. 4
Treatment failure is defined as no improvement in ferritin levels or hemoglobin after an adequate trial of oral iron (typically 2-4 weeks). 4, 3 Only 21% of early non-responders to oral iron will respond to continued oral therapy, compared to 65% who respond to IV iron. 4
Severe Anemia
- Hemoglobin below 10 g/dL (100 g/L) is an indication for IV iron as first-line therapy. 5, 2, 3 This threshold allows for more rapid correction of severe anemia. 5
Malabsorption Conditions
Active Inflammatory States
Patients with clinically active inflammatory bowel disease should receive IV iron as first-line therapy. 1, 2, 3 Inflammation upregulates hepcidin, which blocks intestinal iron absorption, rendering oral iron ineffective. 4, 2
Congestive heart failure patients with iron deficiency (ferritin <100 ng/mL or ferritin 100-300 ng/mL with transferrin saturation <20%) benefit from IV iron to improve exercise capacity. 4, 6
Ongoing Blood Loss
- Patients with chronic gastrointestinal blood loss exceeding intestinal absorption capacity (portal hypertensive gastropathy, gastric antral vascular ectasia, angiodysplasia) require IV iron. 3, 7
Diagnostic Criteria Before IV Iron
Iron deficiency is confirmed when: 4, 2, 6
- Ferritin ≤100 ng/mL, OR
- Ferritin ≤300 ng/mL when transferrin saturation ≤30% (in inflammatory states)
Hemoglobin thresholds defining anemia: 4, 2
- <12 g/dL in women
- <13 g/dL in men
Administration Considerations
Formulation Selection
Choose IV iron formulations that replace iron deficits in 1-2 infusions (ferric carboxymaltose, iron isomaltoside, low molecular weight iron dextran) over those requiring multiple doses. 1, 3 This improves convenience and compliance.
Ferric carboxymaltose is FDA-approved for patients with intolerance or unsatisfactory response to oral iron, allowing doses up to 750 mg per infusion (maximum 1,500 mg total). 6
Safety Profile
All IV iron formulations have similar safety profiles; true anaphylaxis is very rare (<0.1%). 1, 3 Most reactions are complement activation-related pseudo-allergies (infusion reactions), not true allergic reactions. 1, 3
Low molecular weight iron dextran requires a test dose due to boxed warning for anaphylaxis risk. 4 Newer formulations (iron sucrose, ferric gluconate, ferumoxytol, ferric carboxymaltose) do not require test doses. 4
Clinical Scenarios Where Oral Iron May Be Appropriate
Oral iron can be considered first-line only when ALL of the following are present: 1, 2
- Mild anemia (hemoglobin >10 g/dL)
- Clinically inactive disease (no active inflammation)
- No previous intolerance to oral iron
- No malabsorption conditions
Even in these cases, alternate-day dosing (rather than daily) may improve tolerance and absorption by avoiding hepcidin upregulation. 4, 1
Common Pitfalls to Avoid
Do not continue oral iron indefinitely without reassessing response. Check ferritin and hemoglobin after 2-4 weeks; lack of improvement mandates switching to IV iron. 4, 3
Do not assume oral iron will work in inflammatory conditions. Elevated hepcidin blocks absorption regardless of dose or formulation. 4, 2
Do not withhold IV iron due to outdated safety concerns. Modern formulations have excellent safety profiles when administered appropriately. 4, 1, 3, 8
Do not forget to investigate underlying causes of iron deficiency, particularly gastrointestinal malignancy in appropriate populations. 4